Abstract
Introduction: We propose in this study to analyze the results obtained in the experience of Dar El Amal by comparing the two age groups 45-49 years versus over 50 years. This experience of Dar Al Amal was started in Sfax (Tunisia) in 2004. The project had included women over a period of six and a half years. The target population was all women over the age of 45 years.
Results: In the period of the study, 10 000 women had at least one mammography within the first round in Dar El Amal. The average age was 51.56 years. The recall rate was more important in women aged 45-49 years compared with those over 50 years with a statistically significant relationship (p=0.013). Tests classified ACR0 and ACR3 predominated in women aged between 45 and 49 years with a statistically significant relationship. The positive predictive value (PPV) of mammography was better in those over 50 years (p=0.012).
Conclusion: The majority of countries in the world opt for screening from the age of 50 years. Women under 50 years are not routinely concerned, but they have more right to a targeted and appropriate screening.
Keywords: Screening, mammography, breast cancer.
Reviews on Recent Clinical Trials
Title:A Comparative Study of Breast Cancer Screening by Age Across 10000 Tunisian Women
Volume: 11 Issue: 3
Author(s): Jamel Daoud, Wala Ben Kridis, Fatma Elloumi, Inès Ayedi, Wafa Mnejja, Ouhoud Yaiche and Mounir Frikha
Affiliation:
Keywords: Screening, mammography, breast cancer.
Abstract: Introduction: We propose in this study to analyze the results obtained in the experience of Dar El Amal by comparing the two age groups 45-49 years versus over 50 years. This experience of Dar Al Amal was started in Sfax (Tunisia) in 2004. The project had included women over a period of six and a half years. The target population was all women over the age of 45 years.
Results: In the period of the study, 10 000 women had at least one mammography within the first round in Dar El Amal. The average age was 51.56 years. The recall rate was more important in women aged 45-49 years compared with those over 50 years with a statistically significant relationship (p=0.013). Tests classified ACR0 and ACR3 predominated in women aged between 45 and 49 years with a statistically significant relationship. The positive predictive value (PPV) of mammography was better in those over 50 years (p=0.012).
Conclusion: The majority of countries in the world opt for screening from the age of 50 years. Women under 50 years are not routinely concerned, but they have more right to a targeted and appropriate screening.
Export Options
About this article
Cite this article as:
Daoud Jamel, Kridis Ben Wala, Elloumi Fatma, Ayedi Inès, Mnejja Wafa, Yaiche Ouhoud and Frikha Mounir, A Comparative Study of Breast Cancer Screening by Age Across 10000 Tunisian Women, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160502155844
DOI https://dx.doi.org/10.2174/1574887111666160502155844 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Targeted Cancer Therapies: Current Status and Future Directions (Guest Editors: Ioannis Starakis)]
Current Medicinal Chemistry Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagyetween Apoptosis and Autophagy
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets